SCHEMBL10276435

SCHEMBL10276435

COC(=O)Nc1cc(C)ccn1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 4/20 0.60
SMN1; SMN2 Q16637 6/20 0.57
ALDH1A1 P00352 4/20 0.57
MAPK10 P53779 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
NPC1 O15118 9/20 0.56
RAB9A P51151 9/20 0.56
PKM P14618 4/20 0.56
KDM4E B2RXH2 2/20 0.56
MAPT P10636 2/20 0.56
GLA P06280 1/20 0.56
MITF O75030 1/20 0.56
XBP1 P17861 1/20 0.56
HTT P42858 1/20 0.56
HPGD P15428 1/20 0.53
GBA1 P04062 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C19 P33261 1/20 0.52
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL828560 0.83 TP53 (0.51) TP53SMN1; SMN2ALDH1A1MAPK10L3MBTL1
SCHEMBL829141 0.83 RAB9A (0.62) TP53SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL21348778 0.83 NPC1 (0.53) TP53SMN1; SMN2ALDH1A1MAPK10L3MBTL1
SCHEMBL10276470 0.83 SMN1; SMN2 (0.59) TP53SMN1; SMN2ALDH1A1MAPK10L3MBTL1
SCHEMBL25600283 0.82 JAK2 (0.52) TP53SMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL91475 0.81 ALDH1A1 (0.60) TP53SMN1; SMN2ALDH1A1L3MBTL1NPC1
SCHEMBL16705406 0.81 JAK2 (0.55) TP53JAK2JAK1TYK2
SCHEMBL29294853 0.81 JAK2 (0.51) JAK2JAK1TYK2
SCHEMBL16923772 0.81 JAK2 (0.51) TP53SMN1; SMN2ALDH1A1L3MBTL1NPC1
SCHEMBL15432242 0.81 JAK2 (0.55) JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3143026-B1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS NOVARTIS AG (CH) 2024-07-10 EP disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 WO disclosed
WO-2023108103-A1 RAF KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC (US) 2023-06-15 WO disclosed
US-10660881-B2 Compounds and compositions for inducing chondrogenesis NOVARTIS AG (CH) 2020-05-26 US disclosed
US-20190314348-A1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2019-10-17 US disclosed
US-20190134012-A1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION (GNF) 2019-05-09 US disclosed
US-10188638-B2 Compounds and compositions for inducing chondrogenesis NOVARTIS AG (CH) 2019-01-29 US disclosed
US-20170239227-A1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-08-24 US disclosed
US-20170239227-A1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION 2017-08-24 US disclosed
US-9688689-B2 Compounds and compositions for inducing chondrogenesis NOVARTIS AG (CH) 2017-06-27 US disclosed
US-9688689-B2 Compounds and compositions for inducing chondrogenesis NOVARTIS AG (CH) 2017-06-27 US disclosed
US-20150329554-A1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS NOVARTIS AG (CH) 2015-11-19 US disclosed
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-30 US disclosed
US-20120028920-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. 2012-02-02 US disclosed
US-8071600-B2 Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2011-12-06 US disclosed
WO-2011119518-A1 SOLUBLE GUANYLATE CYCLASE ACTIVATORS MERCK SHARP & DOHME CORP. (US) 2011-09-29 WO disclosed
WO-2007026959-A2 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150329554-A1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS FGF1, COL2A1, FGFR3 TP53 739/4885SMN1; SMN2 2011/4885ALDH1A1 27/4885
US-10188638-B2 Compounds and compositions for inducing chondrogenesis FGF1, COL2A1, FGFR3 TP53 739/4885SMN1; SMN2 2011/4885ALDH1A1 27/4885
US-20120028920-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS GRIN2C, GRIN2B, PMP22 TP53 4846/4885SMN1; SMN2 311/4885ALDH1A1 408/4885
US-20190314348-A1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS FGF1, COL2A1, FGFR3 TP53 739/4885SMN1; SMN2 2011/4885ALDH1A1 27/4885
US-20140031334-A1 DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS GRIN2C, GRIN2B, PMP22 TP53 4846/4885SMN1; SMN2 311/4885ALDH1A1 408/4885
US-20170239227-A1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS FGF1, COL2A1, FGFR3 TP53 739/4885SMN1; SMN2 2011/4885ALDH1A1 27/4885
US-10660881-B2 Compounds and compositions for inducing chondrogenesis FGF1, COL2A1, FGFR3 TP53 739/4885SMN1; SMN2 2011/4885ALDH1A1 27/4885
US-20190134012-A1 COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS FGF1, COL2A1, FGFR3 TP53 739/4885SMN1; SMN2 2011/4885ALDH1A1 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.